Don't close the book on tocilizumab for the treatment of severe COVID-19 pneumonia - the jury is still out. The Kuwait experience

Yousef Al-Shamali, Yaser M. Ali, Rawan A. Al-Shamali, Maryam Al-Melahi, Farah R. Al-Shammari, Ahmad Alsaber, Wasl Al-Adsani

Research output: Contribution to journalArticlepeer-review

Abstract

This cross-sectional observational study aims to report preliminary data from the first experience with tocilizumab administered to patients with severe SARS-CoV-2 infection in three of the largest public hospitals in Kuwait City.
Patients and Methods
We conducted a chart review of 127 patients classified as having severe COVID-19 pneumonia with associated features of cytokine release storm treated with tocilizumab.
Results
90 of 127 patients (71%) survived. Mortality was highest in the elderly with multiple medical conditions.
Conclusion
Despite the small sample size and retrospective nature of the work, our findings suggest tocilizumab administration in patients presenting with severe COVID pneumonia with associated cytokine release storm conferred mortality benefit.
Original languageEnglish
Article numbere0254379
Number of pages8
JournalPLOS One
Volume16
Issue number8
DOIs
Publication statusPublished - 24 Aug 2021

Keywords

  • tocilizumab
  • severe COVID-19 pneumonia
  • cytokine Release Storm
  • hyperinflammatory state

Fingerprint

Dive into the research topics of 'Don't close the book on tocilizumab for the treatment of severe COVID-19 pneumonia - the jury is still out. The Kuwait experience'. Together they form a unique fingerprint.

Cite this